A Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging Study to Assess the Safety and Tolerability of ST-920, a AAV2/6 Human Alpha Galactosidase A Gene Therapy, in Subjects with Fabry Disease

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: 18 years and over
This study is NOT accepting healthy volunteers

Inclusion Criteria:
- at least 18 years of age - diagnosis of Fabry disease - one or more of the following symptoms: i) cornea verticillata, ii) acroparesthesia, iii) anhidrosis, iv) angiokeratoma - fully vaccinated for COVID-19 per CDC guidance - additional requirements apply for cardiac and renal groups (study staff will review)

Exclusion Criteria:
- history of liver disease - current or history of use in the last six months of systemic steroids - other significant medical & mental health diagnosis (study staff will review)

Conditions & Interventions

Conditions:
Rare Diseases
Keywords:
Fabry Disease

More Information

Study Contact: Brenda Diethelm-Okita - dieth001@umn.edu
Principal Investigator: Chester Whitley, MD, PhD
Phase: Phase 1/Phase 2
IRB Number: STUDY00007094

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.